ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "EP 78: Your Guide to Lipoprotein(a) with Dr. Salim S Virani"
Episode Synopsis
This week’s Parallax episode is focusing on the latest science and questions surrounding one of the conundrums of cardiovascular science: Lipoprotein(a).
Dr. Ankur Kalra invites Dr Salim S Virani to help simplify the concept of Lp(a) with answering key questions about its measurement and its place in practice and prevention.
Dr Virani is a Professor at Baylor College of Medicine, Director of the Cardiovascular Disease Fellowship Program and Vice Provost of Research at Aga Khan University from early next year.
Lp(a) was first described in 1963. Since then, many epidemiologic studies have noted association of high Lp(a) levels with elevated risk of cardiovascular disease, however, the role of this particle remained a conundrum (Kamstrup, 2017). New data from the development of novel drugs are offering strong evidence on the causality between Lp(a) and ASCVD and AVS (Kronenber et al. 2022).
Dr Virani, one of the authors of the new European Atherosclerosis Society consensus statement on Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis, summarises the key concepts, shares his advice on clinical practice and talks about emerging therapies.
What is Lp(a) and what are the main associations? In what patient population should we lower LP(a)? What do you tell patients about Lp(a) testing and how easy it is to get it tested?
Questions and comments can be sent to “[email protected]” and may be answered by Ankur in the next episode.
Guest: @virani_md, host: @AnkurKalraMD and produced by: @RadcliffeCARDIO.
Dr. Ankur Kalra invites Dr Salim S Virani to help simplify the concept of Lp(a) with answering key questions about its measurement and its place in practice and prevention.
Dr Virani is a Professor at Baylor College of Medicine, Director of the Cardiovascular Disease Fellowship Program and Vice Provost of Research at Aga Khan University from early next year.
Lp(a) was first described in 1963. Since then, many epidemiologic studies have noted association of high Lp(a) levels with elevated risk of cardiovascular disease, however, the role of this particle remained a conundrum (Kamstrup, 2017). New data from the development of novel drugs are offering strong evidence on the causality between Lp(a) and ASCVD and AVS (Kronenber et al. 2022).
Dr Virani, one of the authors of the new European Atherosclerosis Society consensus statement on Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis, summarises the key concepts, shares his advice on clinical practice and talks about emerging therapies.
What is Lp(a) and what are the main associations? In what patient population should we lower LP(a)? What do you tell patients about Lp(a) testing and how easy it is to get it tested?
Questions and comments can be sent to “[email protected]” and may be answered by Ankur in the next episode.
Guest: @virani_md, host: @AnkurKalraMD and produced by: @RadcliffeCARDIO.
More episodes of the podcast Parallax by Ankur Kalra
EP 145: From NAFLD to MASLD: Unveiling the Cardiovascular Impact of Metabolic Liver Disease
27/10/2025
EP 142: The Psychology of Patient Care: Nudges, Gamification, and the Future of Cardiology
08/09/2025
EP 141: From EMPA-REG to Clinical Practice: Mastering SGLT2 Inhibitors in Modern Cardiology
26/08/2025
In God we trust